Prognosis
Gilead’s Drug Leads Global Race for Coronavirus Treatment
- China hasn’t granted full patents; trial results due April 27
- Japan health minister mentions flu drug from Fujifilm
This article is for subscribers only.
China will release results at the end of April from clinical trials of a Gilead Sciences Inc. drug that is emerging as a frontrunner in the race to find an effective treatment for the novel coronavirus.
The outcome of trials of the experimental medication remdesivir on 761 patients in Wuhan, the city where the virus originated, will be made public on April 27, China’s National Intellectual Property Administration said Tuesday.